Dear CGT Innovator,

At CytoNiche，we’re redefining the future of cell therapy manufacturing. Join us at ISCT 2025 to experience 3D FloTrix™ – the first fully integrated, closed-system platform for scalable, cost-effective production of clinical-grade MSCs and other biologics.

[ Why 3D FloTrix™ ? ]

Dissolvable Microcarriers:

Achieve simplified cell production with zero harvest complexity.

Automated & Closed Processes:

Single-use systems eliminate contamination risks and slash labor costs by 80%.

FDA Master Files & Proven Success:

Backed by cGMP-grade consumables and an approved cell therapy in market.

Scalable from R&D to Commercial:

Seamlessly transition from seed train to fill-finish with 50% less downtime.

Schedule a Private Meet → marketing@cytoniche.com

[ Trusted by Leading Trials ]

Our technology powers 10+ active/upcoming clinical trials across:

◈ MSC-Based Regenerative Medicine

◈ MSC-Derived Exosomes

◈ Animal Health

[Why Visit Us?]

Discover how to:

▶ Scale adherent cell culture without suspension adaptation

▶ Reduce COGS by 40% with automated workflows

▶ Accelerate IND filings with pre-reviewed FDA Master Files

New for 2025: Ask us about our 3D RecomTrix™ CW Series – recombinant collagen microcarriers optimized for MSC production!

[Connect with us:]

 : marketing@cytoniche.comwangzhan

 : en.cytoniche.com
 : linkedin.com/company/cytoniche
 : wa.me/6589686988

[Company Profile]

CytoNiche^TM is revolutionizing the cell and gene therapy (CGT) industry with its scalable 3D FloTrix^TM technology, offering comprehensive solutions for CGT manufacturing. Our product portfolio includes GMP-grade dissolvable microcarriers, serum-free media for mesenchymal stromal/stem cells, and a complete suite of GMP-compliant equipment and consumables. These solutions support every stage of cell production—from expansion and harvesting to processing and filling.

Driven by a vision to ignite a new era in industrial cell development, we are empowering CGT advancements through intelligent, 3D cellular mass manufacturing technology. This innovation not only reduces production time and costs but also improves scalability, making it possible to produce billions of high-quality cells more efficiently than traditional methods.

Backed by extensive industry experience and supported by FDA Master Files, our core technology is already being used in several upcoming registered clinical trials, as well as in a successfully commercialized therapeutic. Whether you're working with mesenchymal stem cells (MSCs), exosomes, or other future technologies based on adherent cells, our systems are designed to meet the growing demands of the CGT field.

By reducing facility footprint, labor costs, and contamination risks, our technology is helping shape the future of sustainable biomanufacturing, bringing us closer to benefiting more patients around the world.